Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Martin Shkreli violating lifetime pharma industry ban, US FTC, states says

13 October 2026 · By · Wire by Fusion42

Published

13 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at mlex.com →

◆ Verified

Fusion42 · 14 October 2026 · Fusion42 review

Martin Shkreli has repeatedly violated a 2022 court order banning him from the pharmaceutical industry, leading the US Federal Trade Commission and seven states to seek contempt sanctions including divestment of his pharmaceutical stock and fines equivalent to his trading profits.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 13 Oct 2026 and 14 Oct 2026.

◆ ◆ The Wire takeaway

Legal penalties for violating industry bans in pharma are tightening sharply. You face rising risks if your company trades with or employs barred executives, making compliance a top priority now.

◆ Coverage

8 sources · first reported 13 Oct 2026 · latest 14 Oct 2026

◆ Topics

Biotechpharma-banregulatory-enforcementftclegal-sanctions